[PDF][PDF] Efficacy and safety of erlotinib versus chemotherapy in second-line advanced non-small-cell lung cancer (NSCLC) with poor prognosis: The phase III TITAN …
T Ciuleanu, L Stelmakh, S Cicenas, EE Gonzalez - Chemotherapy (n= 74) - academia.edu
Background: Erlotinib, docetaxel and pemetrexed are all approved in the second-line setting
for patients with advanced NSCLC who progress following first-line platinum doublet …
for patients with advanced NSCLC who progress following first-line platinum doublet …
[引用][C] 88PD EFFICACY AND SAFETY OF ERLOTINIB VERSUS CHEMOTHERAPY IN SECOND-LINE ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) …
T Ciuleanu, L Stelmakh, S Cicenas, EE Gonzalez - Lung Cancer, 2011 - infona.pl
88PD EFFICACY AND SAFETY OF ERLOTINIB VERSUS CHEMOTHERAPY IN SECOND-LINE
ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH POOR PROGNOSIS: THE …
ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH POOR PROGNOSIS: THE …
[引用][C] Efficacy and safety of erlotinib versus chemotherapy in second-line advanced non-small-cell lung cancer (nsclc) with poor prognosis: The phase III Titan study
T Ciuleanu, L Stelmakh, S Cicenas… - Lung …, 2011 - digibuo.uniovi.es
Efficacy and safety of erlotinib versus chemotherapy in second-line advanced non-small-cell
lung cancer (nsclc) with poor prognosis: The phase III Titan study RUO Principal Repositorio …
lung cancer (nsclc) with poor prognosis: The phase III Titan study RUO Principal Repositorio …